REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.26 +1.97%

+$0.16 today

Market cap
$480.05M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.70M

Average 1.24M

Income Statement

Follow revenue through to earnings.

Revenue

$170.44M

FY 2025 · Annual

+104.5% YoY

Operating Income

-$161.20M

FY 2025 · Annual

Net Income

-$193.88M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue470.35M112.72M90.24M83.33M170.44M
Cost of Revenue51.83M54.55M37.21M33.57M20.3M
Gross Profit418.51M58.18M53.03M49.76M150.14M
Gross Margin89.0%51.6%58.8%59.7%88.1%
Research & Development181.44M242.45M232.27M208.52M228.3M
Selling, General & Admin79.33M85.28M88.49M76.62M82.86M
Operating Expenses258.53M321.06M321.16M283.11M311.34M
Depreciation & Amortization9.56M12.91M17.32M16.22M15.62M
EBITDA177.09M(244.24M)(239.46M)(198.23M)(133.26M)
EBITDA Margin37.7%-216.7%-265.4%-237.9%-78.2%
Operating Income159.98M(262.88M)(268.13M)(233.35M)(161.2M)
Operating Margin34.0%-233.2%-297.1%-280.0%-94.6%
Interest Income719K342K25K174K12.27M
Interest Expense26.28M23.25M6.86M12.66M45.01M
Other Income / Expenses(18.73M)(17.53M)4.48M6.24M(32.68M)
Income Before Tax141.25M(280.41M)(263.65M)(227.1M)(193.88M)
Pre-Tax Margin30.0%-248.8%-292.2%-272.5%-113.8%
Income Tax Expense13.41M(84K)(152K)00
Net Income127.84M(280.32M)(263.49M)(227.1M)(193.88M)
Net Margin27.2%-248.7%-292.0%-272.5%-113.8%
EPS (Basic)3.01(6.50)(6.02)(4.59)(3.76)
EPS (Diluted)2.91(6.50)(6.02)(4.59)(3.76)
Weighted Avg Shares42.44M43.15M43.73M49.51M51.57M
Weighted Avg Shares (Diluted)43.91M43.15M43.73M49.51M51.57M

RGNX Earnings Waterfall · TTM

NASDAQ:RGNX · Revenue to Net Income

Key Ratios

EPS$-5.60
Gross Margin-10.8%
Net Margin-542.5%
P/E Ratio-1.9
P/S Ratio32.5

Analysis

$87.8M of revenue converted into -$290.0M of net income for the selected period. Gross margin is -10.8% and net margin is -542.5%, showing how much revenue survives after costs and taxes. EPS is $-5.60, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
4Statement of changes in beneficial ownershipNov 3, 2026

How much revenue does RGNX generate?

REGENXBIO Inc. (RGNX) reported $170.44M of revenue in fiscal 2025.

Is RGNX profitable?

REGENXBIO Inc. (RGNX) reported -$193.88M of net income, with a net margin of -113.8%.